MAGEA3 and melanoma: To validate the prognostic model, we utilized several independent cohorts, including the training cohort TCGA-SKCM, conventional melanoma cohorts (GSE59455 and GSE65904), a stage III melanoma cohort (GSE54467), the anti-PD1 immune checkpoint blockade (ICB) cohort, and the MAGE-A3 immunotherapy cohort.